NCT06955936Recruiting
Efferon CT Hemoadsorption for Cardiogenic Shock in Acute Myocardial Infarction
An Open Randomized Study on the Efficacy and Safety of Hemoadsorption With Efferon CT in Patients With Cardiogenic Shock Complicating Acute Myocardial Infarction
Source: ClinicalTrials.gov · Last updated 26 Aug 2026
Brief summary (registry, in English)
Cardiogenic shock is the most severe manifestation of acute heart failure and remains the leading cause of death in patients hospitalised with acute myocardial infarction. Cardiogenic shock is a well-known and potent trigger of the immune response, ischemia/reperfusion organ damage, hemolysis and release of free hemoglobin. The activation of immune cells leads to the release of cytokines and inflammatory mediators such as IL-6, IL-8, activated complement and others. As a result of myocardial ischaemia and reperfusion injury, a multiorgan dysfunction syndrome may develop. The Efferon CT hemoadsorption device effectively removes cytokines and other pro-inflammatory molecules (≤55 kDa). This study evaluates whether this blood-filtering therapy can prevent organ failure in acute myocardial infarction patients with cardiogenic shock by eliminating inflammation-inducing mediators.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 60 (estimated)
- First submitted
- 25 Apr 2025
- Start date
- 29 Apr 2025
- Primary completion date
- 29 Apr 2027
- Lead sponsor
- Efferon JSC
- Diseases
- Coronary artery disease
- NCT number
- NCT06955936
What you commit to
- Study type: Interventional
- Planned participants: 60
- From 29 Apr 2025 to the primary completion date, 29 Apr 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Broken-heart syndrome (takotsubo cardiomyopathy)
- Acute myocardial infarction within the last 4 weeks
- Cardiac trauma
- Chronic kidney disease, stage 5 D (requiring continuous hemodialysis)
- Patients on immunosuppressive therapy for cancer and autoimmune diseases
- Any other clinical condition of the patient that in the opinion of the investigator precludes inclusion in this study
Other
- Postcardiotomy cardiogenic shock
- Myocarditis
- Charlson comorbidity index greater than 9 points
- Acute pulmonary embolism
- Acute cerebral circulatory collapse
- Transfusion reaction
- Pregnancy
Who the study is looking for
- Not more than 4 hours after diagnosis Cardiogenic shock complicating acute myocardial infarction
- Stages B - C of cardiogenic shock according to SCAI
- Patient condition allows treatment with Efferon® CT device for at least 4 hours
- SOFA score 12 or less
Age in the registry: 18 years to 80 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Tomsk NRMC Cardiology Research Institute Coordinator of this site? Confirm its status | Tomsk | Russia | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.